Skip to main content
Premium Trial:

Request an Annual Quote

Renalytix, Vector Pharma Ink Middle East Distribution Agreement

NEW YORK – Renalytix on Friday announced a distribution agreement with Vector Pharma to make the KidneyIntelX.dkd test for diabetic kidney disease commercially available in the Gulf Cooperation Council (GCC) states of Saudi Arabia, Bahrain, Qatar, Oman, Kuwait, and United Arab Emirates.

Under the agreement, the terms of which were not disclosed, Vector Pharma will initially focus its efforts on building awareness and driving test adoption to reach specified annual sales goals in the six territories.

KidneyIntelX is an artificial intelligence-enabled prognostic testing platform that stratifies adults with type 2 diabetes (T2D) and early-stage chronic kidney disease (CKD) into low-, intermediate-, or high-risk for developing rapid progressive kidney function decline.

The US Food and Drug Administration granted de novo marketing authorization for KidneyInelIX in June.

"When you consider the markets in the Middle East are experiencing high rates of T2D and CKD, diabetic kidney disease management has become a core tenet of many Ministries of Health in the GCC," Patrick Jordan, CEO of Vector Pharma, said in a statement. "Being able to introduce kidneyintelX.dkd to complement the current care protocols will not only benefit the management of individual patients, but it will also address significant objectives to improve chronic disease diagnosis and treatment for the healthcare ecosystem as a whole."

Earlier this year, London-based Renalytix launched a consortium with the goal of demonstrating the utility of biomarker-based tests for predicting drug response in CKD patients. Also this year, the firm raised approximately $20.3 million from securities sales to fund clinical product development, sales and marketing, and other business costs.